{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:04Z","timestamp":1790779924566,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003627","name":"Rural Development Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA000069"],"award-info":[{"award-number":["ZIA000069"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["UG3NS115637"],"award-info":[{"award-number":["UG3NS115637"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-117989RA-I00"],"award-info":[{"award-number":["PID2020-117989RA-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["RYC-2019-027371-I"],"award-info":[{"award-number":["RYC-2019-027371-I"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006521","name":"School of Medicine, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014373","name":"Wu Tsai Neurosciences Institute, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["RF1MH114252"],"award-info":[{"award-number":["RF1MH114252"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopsych.2022.12.019","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T11:24:05Z","timestamp":1671881045000},"page":"1118-1126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4360-1503","authenticated-orcid":false,"given":"Marjorie R.","family":"Levinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan L.","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Di Ianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilya N.","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reece C.","family":"Budinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavin","family":"Shaham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raag D.","family":"Airan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-0151","authenticated-orcid":false,"given":"Jordi","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2022.12.019_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - First FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2022.12.019_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2022.12.019_bib4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2022.12.019_bib5","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib6","article-title":"R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects [published correction appears in Transl Psychiatry 2020;10:295]","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2022.12.019_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms [published correction appears in Pharmacol Rev 2018;70:879]","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2022.12.019_bib9","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.biopsych.2022.12.019_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2022.12.019_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3565(25)21501-4","article-title":"A\u00a0novel phencyclidine analog interacts selectively with mu opioid receptors","volume":"230","author":"Itzhak","year":"1984","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2022.12.019_bib13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biopsych.2022.12.019_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: A review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2009.05.008","article-title":"Kappa-opioid ligands in the study and treatment of mood disorders","volume":"123","author":"Carlezon","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2022.12.019_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0196-0644(96)70319-0","article-title":"Randomized, double-blind, placebo-controlled trial of intravenous ketamine in acute asthma","volume":"27","author":"Howton","year":"1996","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.biopsych.2022.12.019_bib17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1109\/TMI.2022.3148728","article-title":"Deep-fUS: A deep learning platform for functional ultrasound imaging of the brain using sparse data","volume":"41","author":"Di Ianni","year":"2022","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.biopsych.2022.12.019_bib18","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2006"},{"key":"10.1016\/j.biopsych.2022.12.019_bib19","article-title":"6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-diprenorphine ([18F]FE-DPN) preferentially binds to mu opioid receptors in\u00a0vivo [published online Aug 23]","author":"Levinstein","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.biopsych.2022.12.019_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuropharm.2014.07.008","article-title":"Enhancing ketamine translational pharmacology via receptor occupancy normalization","volume":"86","author":"Shaffer","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2022.12.019_bib21","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8369.1","article-title":"Neurobiology of opioid dependence in creating addiction vulnerability [version 1; peer review: 3 approved]","volume":"5","author":"Evans","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.biopsych.2022.12.019_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of \u03bc-opioid receptors: Desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2022.12.019_bib23","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1523\/JNEUROSCI.20-12-04555.2000","article-title":"Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain","volume":"20","author":"Sim-Selley","year":"2000","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.lfs.2005.03.004","article-title":"Mechanisms of mu opioid receptor\/G-protein desensitization in brain by chronic heroin administration","volume":"77","author":"Maher","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/npp.2014.286","article-title":"Mouse model of the OPRM1 (A118G) polymorphism: Differential heroin self-administration behavior compared with wild-type mice","volume":"40","author":"Zhang","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2022.12.019_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/bjp.2008.100","article-title":"Cellular neuroadaptations to chronic opioids: Tolerance, withdrawal and addiction","volume":"154","author":"Christie","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2022.12.019_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: A scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2022.12.019_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/YCO.0b013e3282f32408","article-title":"Major depression and comorbid substance use disorders","volume":"21","author":"Davis","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.64.5.566","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions","volume":"64","author":"Compton","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/npp.2014.261","article-title":"Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders? [published correction appears in Neuropsychopharmacology 2015;40:1307]","volume":"40","author":"Sanacora","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2022.12.019_bib31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.ajp.2014.13101434","article-title":"A\u00a0word to the wise about ketamine","volume":"171","author":"Schatzberg","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1176\/appi.ajp.2021.21060653","article-title":"Mechanisms of action of ketamine and esketamine","volume":"178","author":"Schatzberg","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A\u00a0consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2022.12.019_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J\u00a0Psychoactive Drugs"},{"key":"10.1016\/j.biopsych.2022.12.019_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: Evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2022.12.019_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/02791072.2000.10400244","article-title":"A\u00a0review of the nonmedical use of ketamine: Use, users and consequences","volume":"32","author":"Jansen","year":"2000","journal-title":"J\u00a0Psychoactive Drugs"},{"key":"10.1016\/j.biopsych.2022.12.019_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-3955(01)00012-8","article-title":"MDMA (\u2018ecstasy\u2019) and other \u2018club drugs\u2019. The new epidemic","volume":"49","author":"Koesters","year":"2002","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.biopsych.2022.12.019_bib40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A\u00a0double-blind, randomized, placebo-controlled, dose-frequency\u00a0study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: A PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","article-title":"Dual action of ketamine confines addiction liability","volume":"608","author":"Simmler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2022.12.019_bib44","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1523\/JNEUROSCI.0918-19.2019","article-title":"Separate vmPFC ensembles control cocaine self-administration versus extinction in rats","volume":"39","author":"Warren","year":"2019","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib45","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1523\/JNEUROSCI.0005-12.2012","article-title":"Role of projections from ventral medial prefrontal cortex to nucleus accumbens shell in context-induced reinstatement of heroin seeking","volume":"32","author":"Bossert","year":"2012","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2022.12.019_bib47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ijnp\/pyaa030","article-title":"Effects of mu-opiate receptor gene polymorphism rs1799971 (A118G) on the antidepressant and dissociation responses in esketamine nasal spray clinical trials","volume":"23","author":"Saad","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2022.12.019_bib48","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/s41380-022-01480-3","article-title":"Time will tell. Reply to \u201cComments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et\u00a0al.\u201d by Chen et\u00a0al","volume":"27","author":"Bonaventura","year":"2022","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2022.12.019_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tips.2011.01.002","article-title":"Analytical pharmacology: The impact of numbers on pharmacology","volume":"32","author":"Kenakin","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2022.12.019_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1874473711205030199","article-title":"Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: Molecular implications for opioid tolerance","volume":"5","author":"Garz\u00f3n","year":"2012","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1016\/j.biopsych.2022.12.019_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ijnp\/pyab082","article-title":"Sex differences in the behavioral, molecular, and structural effects of ketamine treatment in depression","volume":"25","author":"Ponton","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2022.12.019_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00737-021-01185-6","article-title":"Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: Findings from short-term randomized, controlled trials","volume":"25","author":"Jones","year":"2022","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.biopsych.2022.12.019_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.biopsych.2012.12.019","article-title":"Effect of chronic delivery of the toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving","volume":"73","author":"Theberge","year":"2013","journal-title":"Biol Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322322018546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322322018546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:08:54Z","timestamp":1762099734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322322018546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0006322322018546"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2022.12.019","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mu Opioid Receptor Activation Mediates (S)-ketamine Reinforcement in Rats: Implications for Abuse Liability","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2022.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}